Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13

Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.